RTI Biologics, Inc. (RTIX) Reports In-Line Q1 EPS; Guides Q211
Tweet
Share
E-mailGet Alerts RTIX Hot Sheet
Price: $3.14 --0%
Financial Fact:
Income tax provision: 92K
Today's EPS Names:
PODC, CLIR, ARDS, More
Financial Fact:
Income tax provision: 92K
Today's EPS Names:
PODC, CLIR, ARDS, More
Join SI Premium – FREE
RTI Biologics, Inc. (Nasdaq: RTIX) reported Q1 EPS of $0.02, in-line with the analyst estimate of $0.02. Revenue for the quarter came in at $40.6 million versus the consensus estimate of $38.32 million.
Sees Q2 2011 EPS of $0.03, versus the consensus of $0.03. Sees Q2 2011 revenue of $40-$41 million, versus the consensus of $40.03 million.
Sees Q2 2011 EPS of $0.03, versus the consensus of $0.03. Sees Q2 2011 revenue of $40-$41 million, versus the consensus of $40.03 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
- Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
